NASDAQ:DNLI - Denali Therapeutics Stock Price, News, & Analysis

$18.71
-0.33 (-1.73 %)
(As of 06/16/2019 04:00 PM ET)
Today's Range
$18.71
Now: $18.71
$19.22
50-Day Range
$18.60
MA: $21.28
$24.71
52-Week Range
$12.32
Now: $18.71
$28.86
Volume264,545 shs
Average Volume290,023 shs
Market Capitalization$1.79 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.28
Denali Therapeutics Inc, a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. The company offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidates, including DNL201 and DNL151, which are in Phase 1 clinical trials for Parkinson's disease. It is also developing receptor interacting serine/threonine protein kinase 1 (RIPK1) product candidates, such as DNL747, a selective and brain-penetrant small molecule RIPK1 inhibitor product candidate that is in Phase 1b clinical trial for Alzheimer's disease and amyotrophic lateral sclerosis (ALS). Read More…

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:DNLI
CUSIPN/A
Phone650-866-8548

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$129.16 million
Book Value$5.76 per share

Profitability

Net Income$-36,240,000.00

Miscellaneous

Employees179
Market Cap$1.79 billion
Next Earnings Date8/8/2019 (Estimated)
OptionableOptionable

Receive DNLI News and Ratings via Email

Sign-up to receive the latest news and ratings for DNLI and its competitors with MarketBeat's FREE daily newsletter.

Denali Therapeutics (NASDAQ:DNLI) Frequently Asked Questions

What is Denali Therapeutics' stock symbol?

Denali Therapeutics trades on the NASDAQ under the ticker symbol "DNLI."

How were Denali Therapeutics' earnings last quarter?

Denali Therapeutics Inc (NASDAQ:DNLI) posted its quarterly earnings results on Wednesday, May, 8th. The company reported ($0.41) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.40) by $0.01. The firm earned $4.21 million during the quarter, compared to the consensus estimate of $12.88 million. Denali Therapeutics had a negative return on equity of 10.23% and a negative net margin of 38.84%. View Denali Therapeutics' Earnings History.

When is Denali Therapeutics' next earnings date?

Denali Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, August 8th 2019. View Earnings Estimates for Denali Therapeutics.

What price target have analysts set for DNLI?

2 brokerages have issued 1-year target prices for Denali Therapeutics' shares. Their forecasts range from $25.00 to $26.00. On average, they expect Denali Therapeutics' share price to reach $25.50 in the next year. This suggests a possible upside of 36.3% from the stock's current price. View Analyst Price Targets for Denali Therapeutics.

What is the consensus analysts' recommendation for Denali Therapeutics?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Denali Therapeutics in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Denali Therapeutics.

Has Denali Therapeutics been receiving favorable news coverage?

Media stories about DNLI stock have been trending somewhat positive recently, InfoTrie Sentiment Analysis reports. InfoTrie rates the sentiment of news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Denali Therapeutics earned a media sentiment score of 1.2 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the stock's share price in the near term. View News Stories for Denali Therapeutics.

Who are some of Denali Therapeutics' key competitors?

What other stocks do shareholders of Denali Therapeutics own?

Who are Denali Therapeutics' key executives?

Denali Therapeutics' management team includes the folowing people:
  • Dr. Ryan J. Watts Ph.D., Co-Founder, Pres, CEO, Chief Scientific Officer & Director (Age 43)
  • Mr. Alexander O. Schuth M.D., Co-Founder, COO & Sec. (Age 46)
  • Dr. Marc Tessier-Lavigne, Co-Founder, Chairman of Scientific Advisory Board & Director (Age 59)
  • Mr. Steve E. Krognes, CFO & Treasurer (Age 50)
  • Dr. Carole Ho, Chief Medical Officer & Head of Devel. (Age 46)

When did Denali Therapeutics IPO?

(DNLI) raised $149 million in an IPO on Friday, December 8th 2017. The company issued 8,300,000 shares at a price of $17.00-$19.00 per share. Goldman Sachs, Morgan Stanley and J.P. Morgan served as the underwriters for the IPO and Evercore ISI was co-manager.

Who are Denali Therapeutics' major shareholders?

Denali Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Baillie Gifford & Co. (6.56%), FMR LLC (5.75%), FIL Ltd (1.33%), Wasatch Advisors Inc. (0.86%), Rhumbline Advisers (0.06%) and New York State Common Retirement Fund (0.06%). Company insiders that own Denali Therapeutics stock include Alexander O Schuth, Carole Ho, Douglas K Bratton and Ryan J Watts. View Institutional Ownership Trends for Denali Therapeutics.

Which institutional investors are selling Denali Therapeutics stock?

DNLI stock was sold by a variety of institutional investors in the last quarter, including FIL Ltd, FMR LLC, American International Group Inc., Zurcher Kantonalbank Zurich Cantonalbank and Rhumbline Advisers. Company insiders that have sold Denali Therapeutics company stock in the last year include Alexander O Schuth, Carole Ho and Ryan J Watts. View Insider Buying and Selling for Denali Therapeutics.

Which institutional investors are buying Denali Therapeutics stock?

DNLI stock was purchased by a variety of institutional investors in the last quarter, including Wasatch Advisors Inc., Baillie Gifford & Co., Spark Investment Management LLC, Dynamic Technology Lab Private Ltd, Marshall Wace LLP, New York State Common Retirement Fund, Ironwood Investment Management LLC and BNP Paribas Arbitrage SA. View Insider Buying and Selling for Denali Therapeutics.

How do I buy shares of Denali Therapeutics?

Shares of DNLI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Denali Therapeutics' stock price today?

One share of DNLI stock can currently be purchased for approximately $18.71.

How big of a company is Denali Therapeutics?

Denali Therapeutics has a market capitalization of $1.79 billion and generates $129.16 million in revenue each year. The company earns $-36,240,000.00 in net income (profit) each year or ($0.39) on an earnings per share basis. Denali Therapeutics employs 179 workers across the globe.View Additional Information About Denali Therapeutics.

What is Denali Therapeutics' official website?

The official website for Denali Therapeutics is http://www.denalitherapeutics.com/.

How can I contact Denali Therapeutics?

Denali Therapeutics' mailing address is 161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 650-866-8548.


MarketBeat Community Rating for Denali Therapeutics (NASDAQ DNLI)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  268 (Thanks for Voting!)
Underperform Votes:  289 (Thanks for Voting!)
Total Votes:  557
MarketBeat's community ratings are surveys of what our community members think about Denali Therapeutics and other stocks. Vote "Outperform" if you believe DNLI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DNLI will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/16/2019 by MarketBeat.com Staff

Featured Article: What Are Cryptocurrencies?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel